Corvert (Ibutilide) — Competitive Intelligence Brief

Corvert (Ibutilide) (Corvert (Ibutilide)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Class III antiarrhythmic agent. Area: Cardiovascular.

marketed Class III antiarrhythmic agent Delayed rectifier potassium channels (hERG); sodium channels Cardiovascular Small molecule

Target snapshot

Corvert (Ibutilide) (Corvert (Ibutilide)) — Medical University of Vienna. Ibutilide is a Class III antiarrhythmic agent that prolongs the cardiac action potential duration by blocking potassium channels and activating inward sodium current.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Corvert (Ibutilide) TARGET	Corvert (Ibutilide)	Medical University of Vienna	marketed	Class III antiarrhythmic agent	Delayed rectifier potassium channels (hERG); sodium channels
iv Amiodarone	iv Amiodarone	Hospital General Universitario Gregorio Marañon	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, calcium channels, beta-adrenergic receptors
(D) HD-V14	(D) HD-V14	National Taiwan University Hospital	marketed	Class III antiarrhythmic agent, beta-blocker
amiodarone amiodarone	amiodarone amiodarone	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
Intravenous amiodarone(1)	Intravenous amiodarone(1)	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	marketed	Class III antiarrhythmic agent	Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors
Amiodarone i.v.	Amiodarone i.v.	Charles University, Czech Republic	marketed	Class III antiarrhythmic agent	Potassium channels (hERG); also sodium channels, beta-adrenergic receptors, and calcium channels
Amiodarone Pill	Amiodarone Pill	Our Lady of the Lake Hospital	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, L-type calcium channels, beta-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Class III antiarrhythmic agent class)

1. Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud · 2 drugs in this class
2. Hippocration General Hospital · 1 drug in this class
3. Hospital General Universitario Gregorio Marañon · 1 drug in this class
4. Medical University of Vienna · 1 drug in this class
5. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
6. National Taiwan University Hospital · 1 drug in this class
7. Charles University, Czech Republic · 1 drug in this class
8. Our Lady of the Lake Hospital · 1 drug in this class